Mikko Hallman – A Major Translator of Basic Science into Neonatal Medicine

References
1 Obituary: Niilo Hallman . Lancet 2011; 377: 634
2 Hallman M, Kulovich M, Kirkpatrick E et al. Phosphatidylinositol and phosphatidylglycerol in amniotic fluid: indices of lung maturity. Am J Obst Gynecol 1976; 125: 613-617
3 Hallman M, Teramo K. Measurement of the lecithin/sphingomyelin ratio and phosphatidylglycerol in amniotic fluid: an accurate method for the assessment of fetal lung maturity. Br J Obst Gynaecol 1981; 88: 806-813
4 Hallman M, Saugstad OD, Porreco RP et al. Role of myoinositol in regulation of surfactant phospholipids in the newborn. Early Hum Devel 1985; 10: 245-254
5 Hallman M, Merritt TA, Schneider H et al. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics 1983; 71: 473-482
6 Chu J, Clements JA, Cotton E et al. Preliminary report: the pulmonary hypoperfusion syndrome. Pediatrics 1965; 35: 733-742
7 Enhörning G, Robertson B. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972; 50: 58-66
8 Hallman M, Merritt TA, Jarvenpaa AL et al. Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective trial. J Pediatr 1985; 106: 963-969
9 Merritt TA, Hallman M, Bloom BT et al. Prophylactic treatment of very premature infants with human surfactant. N Engl J Med 1986; 315: 785-790
10 Merritt TA, Hallman M, Berry C et al. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr 1991; 118: 581-594
11 Revak SD, Merritt TA, Degryse E et al. Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity. J Clin Invest 1988; 81: 826-833
12 Revak SD, Merritt TA, Hallman M et al. The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants. Pediatr Res 1991; 29: 460-465
13 Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993; 328: 861-868
14 Kari MA, Hallman M, Eronen M et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Pediatrics 1994; 93: 730-736
15 Bry K, Hallman M. Transforming growth factor-beta 2 prevents preterm delivery induced by interleukin-1 alpha and tumor necrosis factor-alpha in the rabbit. Am J Obst Gynecol 1993; 168: 1318-1322
16 Bry K, Lappalainen U, Hallman M. Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. J Clin Invest 1997; 99: 2992-2999
17 Emerson GA, Bry K, Hallman M et al. Intra-amniotic interleukin-1 alpha treatment alters postnatal adaptation in premature lambs. Biol Neonate 1997; 72: 370-379
18 Karjalainen MK, Haataja R, Hallman M. Haplotype analysis of ABCA3: association with respiratory distress in very premature infants. Ann Med 2008; 40: 56-65
19 Hallman M, Haataja R. Surfactant protein polymorphisms and neonatal lung disease. Semin Perinatol 2006; 30: 350-361
20 Hallman M, Peltoniemi O, Kari MA. Enhancing functional maturity before preterm birth. Neonatology 2010; 97: 373-378